Topics

Companies Related to "Host mediated ubiquitination mycobacterial protein suppresses immunity" [Most Relevant Company Matches] RSS

13:12 EST 25th February 2020 | BioPortfolio

Here are the most relevant search results for "Host mediated ubiquitination mycobacterial protein suppresses immunity" found in our extensive corporate database of over 50,000 company records.

Showing "Host mediated ubiquitination mycobacterial protein suppresses immunity" Companies 1–25 of 1,200+

Relevant

Cedilla Therapeutics

Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action. The approach harnesses intrinsic degradation pathways that are up...


Prosetta Antiviral Inc.

Prosetta is a 9-year-old San Francisco-based biotechnology company with an innovative approach to drug discovery. The Prosetta platform emerged from 25 years of basic research on cell-free protein synthesizing systems (CFPSS) which validated CFPSS as an effective tool for approaching physiologically important protein-protein interactions, including host-vi...

TissueGene

Starting in 1997, the founders of TissueGene sought to uncover different surgical and gene-based therapeutics for a variety of arthritic conditions. The diligence soon paid off in the form of the first successful animal model for cartilage repair. Subsequently, in the middle of 1999, TissueGene, Inc was incorporated in the United States. TissueGene's initial findings resulted in the focused develo...


Xerion Pharmaceuticals GmbH

Xerion's proprietary protein/ligand identification technology platform, Xcelerate, focuses on the combination of proteome-wide protein separation from any biological source, high-throughput protein identification by mass spectrometry, and simultaneous generation of ligands specific for all the separated proteins. This can replace the lengthy process of gene isolation, subcloning, expression, and r...

Cylex, Inc.

Cylex is a privately held global life science company that is the leader in the development and manufacture of in vitro diagnostic products. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population, and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology pro...

Indapta Therapeutics, Inc.

Indapta Therapeutics is developing off-the-shelf, allogeneic FcεRIγ-deficient NK cells, known as G-NK cells.i,ii,iii These proprietary cells are a specific and potent subset of NK cells with specialized anti-tumor activity when used in combination with a monoclonal antibody. G-NK cells are NK cells that have undergone an epigenetic change after coming into contact with cytomegalovirus (CMV)...

Allergy Immuno Technologies Incorporated

Allergy Immuno Technologies, Inc. (AIT) and its predecessors commenced development activities in allergy and immune disorder research diagnostic reagents and services in 1980. AIT currently operates a clinical reference laboratory at 1527 Monrovia Avenue, Newport Beach, CA, for allergy and other diagnostic testing services for physicians, other laboratories and pharmaceutical companies. As a resul...

Cullgen Inc.

Cullgen is a drug discovery company leveraging ubiquitin-mediated, small molecule-induced protein degradation technology. The company's research programs focus on novel treatment for cancer, inflammatory, and autoimmune diseases. For more information, visit www.cullgen.com.

AC Vaccine technology

The AC Vaccine technology is a therapuetic treatment based on the concept of haptenization. This idea has a long history, beginning with the work of the immunologist and Nobel laureate Karl Landsteiner in the 1920’s. He and other scientists showed in animal models that attaching a small chemical (a hapten) to a protein allowed that protein to be recognized by the immune system even if the anim...

TolerRx Incorporated

TolerRx, Inc. is an emerging biopharmaceutical enterprise specializing in the discovery, development, and commercial launch of a novel class of therapies that induce and/or maintain immunological tolerance. These therapies are most appropriate for chronic conditions associated with adverse, misdirected, or undesirable immune responses. TolerRx's approach is unique and unprecedented, in that it wil...

ProteoChem, Inc.

ProteoChem manufactures protein crosslinkers, analytical standards, and novel proteomics reagents for protein detection and protein modification that are used in mass spectrometry, drug development, diagnostics, and protein biology.

ProMining Therapeutics Ltd

ProMining Therapeutics, Ltd., based in Israel, is an early-stage biopharmaceutical research and development company engaged in the discovery and development of novel oral, small-molecule drugs for a variety of indications including: cancer, inflammation, chronic pain, cardiovascular and viral diseases. The Company has developed CavitIIRx, a proprietary drug discovery and development platform, fo...

Genetic Immunity

US/Hungarian Genetic Immunity and US/Italian ViroStatics, both spin-offs of the non-profit Research Institute for Human and Genetic Therapy (RIGHT), are developing novel treatments for HIV/AIDS and other chronic diseases. The two companies are in the process of merging to form Immunacia – a multinational biopharmaceutical company with Business, Medica...

GloboZymes

GloboZymes is a leading provider of top quality signal transduction enzymes, proteins and antibodies.We maintain a cell signaling, cancer and apoptosis-related research program. Our purified protein kinase, protein phosphatase, protein kinase substrate, modulator protein, protein synthesis initiation factor and affinity-purified antibody preparations generally exhibit greater than 90% homogeneity ...

Sunrise Science Products

Yeast Growth Media High-quality, simple and complex powders made on-site and ready to ship Premixed, complete selective media and individual amino acid dropout mixtures Rich, nonselective media, sugars, supplements and more Standard and custom recipes in large and small scale formats in Vivo Assays for Protein-Protein Interactions in Yeast Screen libraries for interactions with intracellular or in...

Aeras Global TB Vaccine Foundation

ACE BioSciences is an emerging pharmaceutical company focused on developing novel, protein-based vaccines and antibodies to address infectious diseases caused by pathogens such as bacteria, fungi and viruses.ACE BioSciences' competitive advantage is founded on its unique expertise in the extraction and analysis of the cell surface proteins used by pathogens to interact with and infect human host c...

Protein’eXpert SA

Protein’eXpert is a Contract Research & Manufacturing Organisation providing tailor-made target & therapeutic recombinant protein services.Protein’eXpert combines advanced molecular engineering with low-to-high-throughput manufacturing technologies to discover, optimize, produce and deliver R&D-compatible volumes of soluble proteins from genomic sequences.We strive to bring cost-effective and ...

Fusion Antibodies Ltd

Fusion, established in 2001 as a spin-out from Queen’s University Belfast, has won a host of awards for its leading-edge technology platform FET (Fusion Expression Technology). This enabling technology accelerates the validation of targets from DNA sequence through to recombinant protein expression. Fusion generates target specific antibodies from protein antigens with capability, through its an...

ICONIC Protein

ICONIC Protein is one of the fastest-growing brands in the ready-to-drink protein beverage market with a passionate following of health-conscious consumers who have flocked to the brand’s healthy and great-tasting options. Made using dairy protein from grass-fed cows in New Zealand, ICONIC’s ready-to-drink beverage line is hormone, antibiotic and...

IQ Therapeutics BV

IQ Therapeutics BV is a human antibody technology company based in Groningen, The Netherlands. Its mission is to develop instant immunity for healthcare threats, through the development its Instant Immunity(TM) for therapeutic applications in biodefense, infectious diseases and oncology. The company is applying its Cloning the Human Response(TM) technology for its pipeline and third parties' t...

Pierce Biotechnology, Inc.

Pierce Biotechnology, a unit of the Fisher Biosciences group, is one of the first companies researchers turn to when they're conducting protein-studies and related research. Now that the human genome project is completed, researchers are focusing their efforts on the proteins encoded by the mapped genes. Pierce reagents and kits for protein purification, protein detection and quantitation, protein...

Axxima Pharmaceuticals AG

Axximaâ„¢ Pharmaceuticals AG (formerly VirGene) is the leader in the application of pathogen-host signal transduction intervention. The company develops proprietary drugs that are based on Axxima's revolutionary approach to generate a Signal Transduction Firewallâ„¢ (STFâ„¢) against pathogens. Axxima's business strategy is to pursue the highly desirable area of anti-infective drug disc...

Elsevier and Cell Press

Cell Press, an imprint of Elsevier, is committed to improving scientific communication through the publication of exciting research and reviews. Each of our titles is viewed as a must-read by the scientific community it serves. Cell Press primary research journals include the flagship journal Cell, as well as Neuron, Immunity, Molecular Cell, Developmental Cell, Cancer Cell, Current Biology, S...

China Bio-Immunity Corporation

Cobalis

Although Cobalis’ current research is focused on studying the effects of cyanocobalamin (the active ingredient in PreHistin™) on the reduction of symptoms associated with seasonal and perennial allergic rhinitis, we plan to sponsor clinical trials into other immunoglobulin-E (IgE)-mediated allergic diseases to expand our product line. These supplemental indications include: :: Pediatric do...


More From BioPortfolio on "Host mediated ubiquitination mycobacterial protein suppresses immunity"

Quick Search

Corporate Database Quicklinks